Q-Check Pharmaceuticals — Care beyond Healthcare

Alzheimer's Care is Moving from Single-Target (Amyloid) to Multi-Pathway Approach

The approval of amyloid-targeting monoclonal antibodies marked a historic milestone in Alzheimer's treatment. But the clinical community is increasingly recognising that amyloid clearance alone — while necessary — is insufficient for meaningful disease modification. The next chapter of Alzheimer's therapy is being written across three simultaneous targets: amyloid, tau, and neuroinflammation.

Amyloid-Targeting Monoclonals: Current Landscape

Lecanemab and donanemab have demonstrated statistically significant slowing of cognitive decline in clinical trials (2024–2025 data). Patient selection is critical: the greatest benefit is observed in cognitively normal individuals, those with subjective cognitive decline, and early MCI stages — reinforcing the imperative of early, biomarker-driven diagnosis.

ARIA (amyloid-related imaging abnormalities) remains the primary safety concern, occurring in a significant proportion of treated patients and requiring rigorous monitoring protocols.

Tau-Targeting: The Next Frontier

Hydromethylthionine mesylate (HMTM), developed by TauRx Pharmaceuticals, is showing promising phase 3 data (2025). Its mechanism — preventing tau aggregation — targets the second hallmark of Alzheimer's pathology, complementing the amyloid-targeting approach. FDA submission is expected in 2026.

Neuroinflammation: The Third Target

TREM2 and NLRP3 inhibitors are showing significant promise in animal models, with human trials expected in 2026–2027. The neuroinflammatory hypothesis — that sustained microglial activation drives progressive neurodegeneration — offers a third therapeutic lever that may prove essential for durable disease modification.

Blood Biomarkers: Democratising Diagnosis

Plasma phospho-tau and phospho-amyloid panels are achieving 95% predictive value for future cognitive decline — at a cost of ₹5,000–8,000 versus ₹50,000 for PET imaging. This accessibility transformation enables presymptomatic diagnosis at scale.

Research Sources